Welcome to the Enroll-HD Portal, your access point to contribute to the largest database of clinical data for Huntington’s disease (HD). The overarching objective of Enroll-HD is to accelerate the development of therapeutics for HD by: - compiling uniform clinical data and biological samples to better understand the natural history of HD;
- building a more comprehensive database – including biological samples – that will be accessible to any HD investigator worldwide;
- facilitating clinical sub-studies and the development of validated HD assessment tools;
- fostering good clinical care and improving health outcomes for both patients and families;
- expediting recruitment into future global clinical trials of candidate therapeutics.
Enroll-HD Newsletter and Monthly News
Bulletin: The monthly News Bulletin and quarterly newsletter
for research participants and site staff can be found on the  Enroll-HD
website.
Enroll-
HD Study Status:
| Total Participating sites: |
187 |
(179) |
| Participating countries: |
23 |
|
| Total participants: |
30'038 |
(21'414) |
| Total visits: |
153'966 |
|
July 21, 2023. | | Enroll-HD News:
Enroll-HD 1.20.11 (Mar 2025)
- Finish continued data entry of General visits with Submit General for Review
- Finish continued data entry of Family History with Complete Data Entry
- Family History year of birth can be earlier than 1800.
Plasma Collection 1.0 (July 2019)
- Selected sites have been invited to participate in a longitudinal collection of plasma.
- Site selection has been based on several criteria.
- The Enroll-HD EDC has been upgraded to allow to collect plasma from participants.
HDClarity 3.0 (May 2019) - Study protocol 3.0 implemented (annual sampling visits)
- Partial sampling visits possible
- Further enhancements
|
